Characteristics of the JAK2Stroke, GESUS cohort, and case-control populations
| . | JAK2Stroke . | GESUS . | JAK2Stroke AB ≥0.009 (cases) . | Control cohort (GESUS) free of ICVD (controls) . | P cases vs control . |
|---|---|---|---|---|---|
| Population, n | 538 | 19 958 | 538 | 1613 | |
| Age, mean ± SD | 69.5 ± 10.9 | 55.8 ± 13.5 | 69.5 ± 10.9 | 69.2 ± 10.9 | .581 |
| Individuals with JAK2V617F, n (%) | 61 (11.3) | 613 (3.1) | 53 (9.9) | 71 (4.4) | <.001 |
| MPN before inclusion, n (%) | 1 (0.2) | 14 (0.1) | 1 (0.2) | 1 (0.06) | .438 |
| JAK2V617F allele burden | |||||
| <0.009%, n (%) | 8 (13.1) | — | — | — | |
| 0.009%-0.09%, n (%) | 27 (44.3) | 255 (42) | 27 (50.9) | 27 (38.0) | .211 |
| 0.1%-0.9%, n (%) | 11 (18) | 253 (41) | 11 (20.8) | 31 (43.7) | .013 |
| 1%-10%, n (%) | 6 (9.8) | 75 (12) | 6 (11.3) | 9 (12.7) | >.99 |
| >10%, n (%) | 9 (14.8) | 30 (5) | 9 (17.0) | 4 (5.6) | .072 |
| Laboratory values | |||||
| Hemoglobin, g/dL, mean ± SD | 14.1 ± 1.79 | 14.0 ± 1.27 | 14.1 ± 1.79 | 14.08 ± 1.29 | .811 |
| Hematocrit, mean ± SD | 0.42 ± 0.05 | 0.43 ± 0.03 | 0.42 ± 0.05 | 0.43 ± 0.04 | <.001 |
| Platelet count, ×109/L, mean ± SD | 254 ± 88.6 | 251 ± 59 | 254 ± 88.6 | 241 ± 58 | .002 |
| White blood cells, ×109/L, mean ± SD | 8.72 ± 3.17 | 7.29 ± 1.96 | 8.72 ± 3.17 | 7.26 ± 1.95 | <.001 |
| . | JAK2Stroke . | GESUS . | JAK2Stroke AB ≥0.009 (cases) . | Control cohort (GESUS) free of ICVD (controls) . | P cases vs control . |
|---|---|---|---|---|---|
| Population, n | 538 | 19 958 | 538 | 1613 | |
| Age, mean ± SD | 69.5 ± 10.9 | 55.8 ± 13.5 | 69.5 ± 10.9 | 69.2 ± 10.9 | .581 |
| Individuals with JAK2V617F, n (%) | 61 (11.3) | 613 (3.1) | 53 (9.9) | 71 (4.4) | <.001 |
| MPN before inclusion, n (%) | 1 (0.2) | 14 (0.1) | 1 (0.2) | 1 (0.06) | .438 |
| JAK2V617F allele burden | |||||
| <0.009%, n (%) | 8 (13.1) | — | — | — | |
| 0.009%-0.09%, n (%) | 27 (44.3) | 255 (42) | 27 (50.9) | 27 (38.0) | .211 |
| 0.1%-0.9%, n (%) | 11 (18) | 253 (41) | 11 (20.8) | 31 (43.7) | .013 |
| 1%-10%, n (%) | 6 (9.8) | 75 (12) | 6 (11.3) | 9 (12.7) | >.99 |
| >10%, n (%) | 9 (14.8) | 30 (5) | 9 (17.0) | 4 (5.6) | .072 |
| Laboratory values | |||||
| Hemoglobin, g/dL, mean ± SD | 14.1 ± 1.79 | 14.0 ± 1.27 | 14.1 ± 1.79 | 14.08 ± 1.29 | .811 |
| Hematocrit, mean ± SD | 0.42 ± 0.05 | 0.43 ± 0.03 | 0.42 ± 0.05 | 0.43 ± 0.04 | <.001 |
| Platelet count, ×109/L, mean ± SD | 254 ± 88.6 | 251 ± 59 | 254 ± 88.6 | 241 ± 58 | .002 |
| White blood cells, ×109/L, mean ± SD | 8.72 ± 3.17 | 7.29 ± 1.96 | 8.72 ± 3.17 | 7.26 ± 1.95 | <.001 |
The JAK2V617F mutation prevalence, distribution of allele burden, and blood cell levels of the JAK2Stroke cohort, total GESUS population, JAK2Stroke cohort with an applied JAK2V617F detection limit of 0.009%, and age- and sex-matched control cohort from the GESUS population free of ICVD. P values < 0.05 are shown in bold.
AB, allele burden; SD, standard deviation.